Chronic fatigue syndrome, Fibromyalgia, Scleroderma, Lupus, Rheumatoid Arthritis, MCS: the mercury connection. B. Windham (Ed.) 2009.
Chronic fatigue syndrome(CFS) is characterized by fatigue, neurologic symptoms including headaches, brain fog, mood disorders, and motor dysfunction. Millions of people in the U.S. suffer from CFS. An estimated three to six million patients in the US are affected by fibromyalgia (FMS) (581). Spect scans of those with CFS have found that the majority have over 5 times more areas of regional brain damage and reduced blood flow in the cerebral cortex area of the brain(471) than controls. The majority studied were also found to have increased Th2 inflammatory cytokine activity and a blunted DHEA response curve to I.V. ATCH indicative of hypothalamic/adrenal deficiency such as relative glucocorticoid deficiency (472).
CFS and Fibromyalgia patients have also been found to commonly have abnormal enzymatic processes that affect the sodium‑potassium ATPase energy channels(473), which appears to be a major factor in the condition and for which mercury is a known cause(43,288,498). This also has been found to result in inflammatory processes that cause muscle tissue damage and result in higher levels of urinary excretion of creatine , choline, and glycine in CFS, and higher levels of excretion of choline, taurine, citrate, and trimethyl amine oxide in FM(474,593,594). Supplementation of creatine has been found to result in improved muscle mitochondrial function in such patients(502). FM is further characterized by muscle and fibrous tissue pain, and its prevalence has been estimated at greater than 7% in women aged 60-79 years and 3.4% for all women(528). A Swedish study found that in one county, 11.6% of women over 35 surveyed had symptoms of Fibromyalgia, while 5.5% of men reported such symptoms(368). A study found that for a group of patients that had both CFS and FM, all had high homocysteine levels, a marker of inflammation (580,Regland et al, 1997). Other factors in CFS and Fibromyalgia include oxidative stress, metal sensitivity,adrenal fatigue, autoimmunity, leaky gut, organic acid imbalances, food allergies, IBS, digestive malabsorption of essential nutrients, along with overgrowth of intestinal yeasts, bacteria, or parasites (386a,580.581,586). Research suggests that as many as 75% of individuals with fibromyalgia have bacterial overgrowth in the small bowel. Clinical experience has found that the pathogen overgrowths cannot be fully eliminated without detoxification of mercury and toxic metals which facilitate the pathogen overgrowths(581).
Tests also found mercury accumulation in the limbic system and muscle tissues of a sample of fibromyalgia patients tests, and significant improvement after dental revision to replace amalgam fillings and deal with toxic root-canal teeth and cavitations(586).
II. Mercury sources and exposure levels.
Amalgam fillings are the largest source of mercury in most people with daily exposures documented to commonly be above government health guidelines(49,79,506,600). This is due to continuous vaporization of mercury from amalgam in the mouth, along with galvanic currents from mixed metals in the mouth that deposit the mercury in the gums and oral cavity
(600). Due to the high daily mercury exposure and excretion into home and business sewers of those with amalgam, dental amalgam is also the largest source of the high levels of mercury found in all sewers and sewer sludge, and thus a significant source of mercury in rivers, lakes, bays, fish, and crops(603). People also get significant exposure from vaccinations, fish, and dental office vapor(600).
When amalgam was placed into teeth of monkeys and rats, within one year mercury was found to have accumulated in the brain, trigeminal ganglia, spinal ganglia, kidneys, liver, lungs, hormone glands, and lymph glands(20). People also commonly get exposures to mercury and other toxic metals such as lead, arsenic, nickel, and aluminum from food, water, and other sources(601). All of these are highly neurotoxic and are documented to cause neurological damage which can result in chronic neurological conditions over time. Mercury induced lipid peroxidation has been found to be a major factor in mercury’s neurotoxicity, along with leading to decreased levels of glutathione peroxidation and superoxide dismustase(SOD)(13,254,489,494-496). Antioxidants have been found to protect against such mercury neurotoxicity(494,572).
Mercury (especially mercury vapor) rapidly crosses the blood brain barrier and is stored preferentially in the pituitary gland, hypothalamus, thyroid gland, adrenal gland, and occipital cortex in direct proportion to the number and extent of amalgam surfaces (20, many studies referenced in (600)) Thus mercury has a greater effect on the functions of these areas. The range in one study was 2.4 to 28.7 parts per billion(ppb), and one study found on average that 77% of the mercury in the occipital cortex was inorganic(600).
III. Effects of Mercury (and toxic metal) Exposure
Some of the factors documented to be involved in inflammatory conditions like CFS, FMS, Lupus, Rheumatoid Arthritis, etc and in programmed cell death, apoptosis, of neurons and immune cells in degenerative neurological conditions like ALS, Alzheimer’s, MS, Parkinson’s, etc. include inducement of the inflammatory cytokine Tumor Necrosis Factor-alpha(TNFa) (126), reactive oxygen species and oxidative stress (13,43a,56a,296b,386a), reduced glutathione levels(56,126a,111a), liver enzyme effects and inhibition of protein kinase C and cytochrome P450(43,84,260), nitric oxide and peroxynitrite toxicity (43a,521,524), excitotoxicity and lipid peroxidation(490,496), excess free cysteine levels (56d,111a,33,330),excess glutamate toxicity(13b, 416), excess dopamine toxicity (56d,13a), beta-amyloid generation(462,56a), increased calcium influx toxicity (296b,333,416,432,462c,507) and DNA fragmentation (296,42,114,142) and mitochondrial membrane dysfunction (56de, 416), and autoimmunity (313,342,382,405,513). As will be documented, mercury and toxic metals exposure causes all of these factors.
TNFa(tumor necrosis factor-alpha) is a cytokine that controls a wide range of immune cell response in mammals, including cell death(apoptosis). This process is involved in inflammatory conditions like CFS, FM, RA, Lupus, etc. and in degenerative neurological conditions like ALS, MS, Parkinson’s, rheumatoid arthritis, etc. Cell signaling mechanisms like sphingolipids are part of the control mechanism for the TNFa inflammatory and apoptosis mechanism(126a). glutathione is an amino acid that is a normal cellular mechanism for controlling inflamation and apoptosis. When glutathione is depleted in the brain, reactive oxidative species increase, and CNS and cell signaling mechanisms are disrupted by toxic exposures such as mercury, neuronal cell apoptosis results and neurological damage. Mercury has been shown to induce TNFa, deplete glutathione, and increase glutamate, dopamine, and calcium related toxicity, causing inflammatory effects and cellular apoptosis in neuronal and immune cells(126b,126c). Mercury’s biochemical damage at the cellular level include DNA damage, inhibition of DNA and RNA synthesis (42,114,142,197,296,392); alteration of protein structure (33,111,114,194,252,263,442); alteration of the transport and signaling mechanisms of calcium(333,43b,254,263,416d,462,507); inhibitation of glucose transport(338,254), and of enzyme function and transport/absorption of other essential nutrients (96,198,254,263,264,33,330,331,338,339,347,441,442); induction of free radical formation(13a,43b,54,405,424), depletion of cellular glutathione(necessary for detoxification processes) (56,111,126,424), inhibition of glutathione peroxidase enzyme(13a,442), inhibits glutamate uptake(119,416), induces peroxynitrite and lipid peroxidation damage(521b,56b), causes abnormal migration of neurons in the cerebral cortex(149), immune system damage (111,126,181,194,226,252, 272,316,355); affects dopamine uptake by neuronal synaptosomes(288), inducement of inflammatory cytokines(126,152,181), and induces autoimmunity (181,313,342,382,405,etc.). Mercury’s activation of inflammatory cytokines and Th2 helper immune cells suppresses the cytotoxic response of T-cells and natural killer immune cells that are the body’s main defense against viruses and such biological pathogens(181,472,580,581).
A direct mechanism involving mercury's inhibition of cellular enzymatic processes by binding with the hydroxyl radical(SH) in amino acids appears to be a major part of the connection to allergic/immune reactive conditions such as: Lupus (SLE) (331a,330a,33,113,126,181,234,260d,288a,405,270,226, 314,316,263c,456) & Scleroderma (330a,33,126,181,234,468,405,263c) &
Rheumatoid Arthritis(287,288a,416f,331b, 330a,33,126,181,405,263d,260d), as well as CFS and FMS that are also related to inflammatory cytokine processes and autoimmunity (181,118,313,314,342,382,405,126, 330, 33,263,582,etc.). One study found that insertion of amalgam fillings or nickel dental materials causes a suppression of the number of T‑lympocytes(270), and impairs the T‑4/T‑8 ratio. Low T4/T8 ratio has been found to be a factor in lupus, anemia, MS, eczema, inflammatory bowel disease, and glomerulonephritis.
Mercury induced autoimmunity in animals and humans has been found to be associated with mercury's expression of major histocompatibility complex(MHC) class II genes(314,181,226,425c). Both mercuric and methyl mercury chlorides caused dose dependent reduction in immune B‑cell production(316). B‑cell expression of IgE receptors were significantly reduced(316,165), with a rapid and sustained elevation in intracellular levels of calcium induced(316,333).
Mercury and other toxic metals also form inorganic compounds with OH, NH2, CL, in addition to the SH radical and thus inhibits many cellular enzyme processes, coenzymes, hormones, and blood cells(405,600). Mercury has been found to impair conversion of thyroid T4 hormone to the active T3 form as well as causing autoimmune thyroiditis common to such patients(342,382). In general, immune activation from toxic metals such as mercury resulting in cytokine release and abnormalities of the hypothalamus‑pituitary‑adrenal (HPA) axis can cause changes in the brain, hypocortisolism, fatigue, and severe psychological symptoms (348,342,375,379‑382,385,386a,405,118) such as profound fatigue, muscoskeletal pain, sleep disturbances, gastrointestinal and neurological problems as are seen in CFS, Fibromyalgia, and autoimmune thyroiditis. Such hypersensitivity has been found most common in those with genetic predisposition to heavy metal sensitivity (60,313,342,405), such as found more frequently in patients with human lymphocyte antigens (HLA‑DRA) (381-383). A significant portions of the population appear to fall in this category.
Mercury exposure through dental fillings appears to be a major factor in chronic fatigue syndrome(CFS) and Fibromyalgia through its effects on ATP and immune system(lymphocyte reactivity, neutraphil activity, effects on T‑cells and B‑cells) as well as its promotion of growth of Candida albicans in the body and the methylation of inorganic mercury by candida and intestional bacteria to the extremely toxic methyl mercury form, which like mercury vapor crosses the blood‑brain barrier, and also damages and weakens the immune system (222,225,226,234,235,265,293,60,313,314,342,404,581, 590). Mercury vapor or Inorganic mercury have been shown in animal studies to induce autoimmune reactions and disease through effects on immune system T cells(226,268,269,270,314). Chronic immune activation is common in CFS, with increase in activated CD8+ cytotoxic T-cells and decreased NK cells(518). Numbers of suppressor-inducer T cells and NK cells have been found to be inversely correlated with urine mercury levels(270ad). CFS and FMS patients usually improve and immune reactivity is reduced when amalgam fillings are replaced (342,383,405,581,590,293).
Heavy metal toxicity has been found to be a common co-factor in FMS , as well as root canaled teeth and jawbone cavitations (582). Nickel has been often found to be a factor in chronic autoimmune conditions like CFS and Lupus (342,456, etc.)
Chronic neurological conditions appear to be primarily caused by chronic or acute brain inflammation. The brain is very sensitive to inflammation. Disturbances in metabolic networks: e.g., immuno-inflammatory processes, insulin-glucose homeostasis, adipokine synthesis and secretion, intra-cellular signaling cascades, and mitochondrial respiration have been shown to be major factors in chronic neurological conditions (592,593,598, etc.). Inflammatory chemicals such as mercury, aluminum, and other toxic metals as well as other excitotoxins including MSG and aspartame cause high levels of free radicals, lipid peroxidation, inflammatory cytokines, and oxidative stress in the brain and cardiovascular systems(13,595-598,386a,etc.) Exposures to heavy metal toxins can impair energy production and burden the detoxification system(386a). Oxidative stress caused by unstable free radical molecules can damage the energy-producing mechanisms inside the body’s cells. Fatigue and/or muscle pain can develop from toxic stress when the body is unable to detoxify harmful waste products or toxins from the environment (386a).
Mercury and other toxic metals inhibit astrocyte function in the brain and CNS(119), causing increased glutamate and calcium related neurotoxicity (119,333,416,496). Mercury and increased glutamate activate free radical forming processes like xanthine oxidase which produce oxygen radicals and oxidative neurological damage(142,13). Nitric oxide related toxicty caused by peroxynitrite formed by the reaction of NO with superoxide anions, which results in nitration of tyrosine residues in neurofilaments and manganese Superoxide Dimustase(SOD) has been found to cause inhibition of the mitochondrial respiratory chain, inhibition of the glutamate transporter, and glutamate-induced neurotoxicity involved in ALS(524,521).
These inflammatory processes damage cell structures including DNA, mitochondria, and cell membranes. They also activate microglia cells in the brain, which control brain inflammation and immunity. Once activated, the microglia secrete large amounts of neurotoxic substances such as glutamate, an excitotoxin, which adds to inflammation and stimulates the area of the brain associated with anxiety (598). Inflammation also disrupts brain neurotransmitters resulting in reduced levels of serotonin, dopamine, and norepinephrine which can lead to depression. (593) Some of the main causes of such disturbances that have been documented include vaccines, mercury, aluminum, other toxic metals, MSG, aspartame, etc. (593,598,600,etc.)
Reduced levels of magnesium and zinc are related to metabolic syndrome, insulin resistance, and brain inflammation and are protective against these conditions (595,43). Mercury and cadmium inhibiting magnesium and zinc levels as well as inhibiting glucose transfer are other mechanisms by which mercury and toxic metals are factors in metabolic syndrome and insulin resistance/diabetes (43,196,338,597).
Fatigue is a hallmark symptom of thyroid or adrenal hormone imbalances (386a,581). Mercury lymphocyte reactivity, effects on glutamate in the CNS, and mercury induced hypothyroidism induce CFS type symptoms including profound tiredness, musculoskeletal pain, sleep disturbances, gastrointestinal and neurological problems along with other CFS symptoms and Fibromyalgia (342,346,405,293). Mercury has been found to be a common cause of Fibromyalgia (293,346,342,523,527,581). Glutamate is the most abundant amino acid in the body and in the CNS acts as excitory neurotransmitter (346,386), which also causes inflow of calcium. Astrocytes, a type of cell in the brain and CNS with the task of keeping clean the area around nerve cells and facilitating neurotransmission, have a function of neutralizing excess glutamate by transforming it to glutamic acid. If astrocytes are not able to rapidly neutralize excess glutamate, then a buildup of glutamate and calcium occurs, causing swelling and neurotoxic effects (119,333). Mercury and other toxic metals inhibit astrocyte function in the brain and CNS(119), causing increased glutamate and calcium related neurotoxicity(119,333,226) which are responsible for much of the Fibromyalgia symptoms. This is also a factor in conditions such as CFS, Parkinson's, and ALS(346,416). Animal studies have confirmed that increased levels of glutamate(or aspartate, another amino acid excitory neurotransmitter) cause increased sensitivity to pain , as well as higher body temperature‑ both found in CFS/Fibromyalgia. Mercury and increased glutamate activate free radical forming processes like xanthine oxidase which produce oxygen radicals and oxidative neurological damage(142,346,13). Medical studies and doctors treating Fibromyalgia have found that supplements which cause a decrease in glutamate or protect against its effects have a positive effect on Fibromyalgia. Some that have been found to be effective include Vit B6, methyl cobalamine(B12), L‑carnitine, choline, ginseng, Ginkgo biloba, vitamins C and E, nicotine, and omega 3 fatty acids(fish and flaxseed oil-GLA,EPA,DHA)(417,229). Other supplements that also have been found to help are magnesium and malic acid(488,489). Avoidance of exictotoxins like MSG and aspartame have been found to eliminate symptoms in some with Fibromyalgia(490).
Clinical tests of patients with chronic neurological conditions, Lupus(SLE), and rheumatoid arthritis have found that the patients generally have elevated plasma cysteine to sulphate ratios, with the average being 500%higher than controls (330,331,600,33e), and in general being poor sulphur oxidizers. This means that these patients have insufficient sulfates available to carry out necessary bodily processes. Mercury has been shown to diminish and block sulphur oxidation and thus reducing glutathione levels which is the part of this process involved in detoxifying and excretion of toxics like mercury(33). Glutathione is produced through the sulphur oxidation side of this process. Low levels of available glutathione have been shown to increase mercury retention and increase toxic effects(111), while high levels of free cysteine have been demonstrated to make toxicity due to inorganic mercury more severe(333,194,33e). Mercury has also been found to play a part in inducing intolerance and neuronal problems through blockage of the P‑450 liver enzymatic process(84,33e).
Mercury from amalgam interferes with production of cytokines that activate macrophage and neutrophils, disabling early control of viruses and leading to enhanced infection(131,251). Mercury’s activation of inflammatory cytokines and Th2 helper immune cells suppresses the cytotoxic response of T-cells and natural killer immune cells that are the body’s main defense against viruses and such biological pathogens(181,472,580). Animal studies have confirmed that mercury increases effects of the herpes simplex virus type 2 for example(131). Mercury damages the immune system and in those with chronic conditions has been found to commonly facilitate infestation by pathogens such as viruses, harmful bacteria, candida, mycoplasma, and parasites(131,251,386a,404,460,470, 473,485). The majority of those tested who have CFS or FMS have been found to have infections of mycoplasma, Human Herpes Virus-6,XMRV, Cytomeglivirus, or bacterial infections such as intracellular chlamydia(470,575,580). Clinics treating these conditions commonly find such pathogens to be a factor in the condition (470,473,485,487,488, 580). Mercury detoxification and treatment of these pathogens results in significant improvement in the majority of those treated (470,485,488,489, 230,581,600). Studies have also found bilberry extract, curcumin, carotenoids, and chlorophyll supplements to be effective in suppressing effects of viruses such as Epstein-Barr (580) or XMRV(575). Supplementation with chlorella has been found to result in beneficial effects when used in patients chronic conditions such as ulcerative colitis, hypertention, or Fibromyalgia(304). Doctors such as D. Klinghardt (581) have suggested that the mechanism by which chlorella improves treatment of such conditions is metals detoxification, which is the main mechanism of action of chlorella and has been found to greatly improve intestinal function.
Mercury exposure causes high levels of oxidative stress/reactive oxygen species(ROS)(13,386a), which has been found to be a major factor in apoptosis and neurological disease (56,250,441,442,443,13) including dopamine or glutamate related apoptosis(288c). Mercury and quinones form conjugates with thiol compounds such as glutathione and cysteine and cause depletion of glutathione, which is necessary to mitigate reactive damage. Such congugates are found to be highest in the brain substantia nigra with similar congugates formed with L-Dopa and dopamine in Parkinson’s disease(56). Mercury depletion of GSH and damage to cellular mitochondria and the increased lipid peroxidation in protein and DNA oxidation in the brain appear to be a major factor in Parkinson’s disease(33,56,442)
IV. Multiple Chemical Sensitivity
Many cases of Multiple Chemical Sensitivity (MCS) develop
following exposures to heavy metal toxins such as mercury(386a).
Mercury exposure results in oxidative stress, reduced glutathione, increased
peroxynitrite, found in virtually all with MCS or CFS or FM, which have
overlapping symptoms and factors. Oxidative stress from reactive free radicals
or deficient glutathione and the resulting increased peroxynitrite can
inactivate important mitochondrial enzymes and interfere with energy production
in MCS or CFS (386a,580). Inherited impairments in detoxification
function can also interact with environmental factors to promote MCS. Defects
in the body’s ability to neutralize environmental chemicals lead directly to
the accumulation of toxins. The body’s
ability to neutralize and excrete environmental toxins depends on the
availability of key nutrients. Some cases of MCS may be secondary to ‘leaky
gut’ and the passage of toxins or food particles into the system. Maldigestion of critical nutrients, as
well as intestinal infection (bacteria, yeast, or parasites) may aggravate
MCS. Intestinal overgrowth of yeast and
the passage of Candida toxins into the system or parasites may further chemical
sensitivities in MCS or CFS(386a,580).
V. Treatment of CFS, Fibromyalgia, Multiple Chemical Sensitivity, etc.
It has been well documented by hundreds of medical studies including thousands of tested subjects and by scientific panels that "amalgam fillings" are the largest source of mercury in people and that those with several amalgam fillings often have daily exposures exceeding the Government Health Standards for mercury(600). Thus among those most susceptible, significant neurological and immune effects related to amalgam fillings are common. Symptoms of those with CFS, Fibromyalgia, or thyroid related conditions usually improve significantly after proper amalgam replacement. In thousands of cases undergoing amalgam replacement, the majority recovered or had significant improvement in symptoms for muscular/joint pain/ Fibromyalgia (222,293,317,322,342,440,469,470,523,527, 94), Chronic Fatigue Syndrome(CFS) (8,27,60,212,230,293,229,222,232,233,271,293,313, 317,320,342,375,376,382,440,469,470,485,590,35), lupus (342,113,222, 229,233,323,35), autoimmune thyroiditis (342,382), multiple chemical sensitivities (26,27,35,60,62,95,222,229,232,233,115,313,321, 342,537,583), as well as many other conditions(600). Of one group of 86 patients with CFS symptoms, 78% reported significant health improvements after replacement of amalgam fillings within a relatively short period, and the MELISA immune reactivity test found significant reduction in lymphocyte reactivity compared to pre removal tests(342,375). The improvement in symptoms and lymphocyte reactivity imply that most of the Hg‑induced lymphocyte reactivity is allergenic in nature. Although patch tests for mercury allergy are often given for unresolved oral symptoms, this is not generally recommended as a high percentage of such problems are resolved irrespective of the outcome of a patch test (60,87,90,etc.)
Exposure to organochlorine compounds such as DDT/DDE and hexachlorobenzene have also been found to be highly correlated with chronic fatigue. Sick building syndrome (SBS) related to toxic exposures is usually characterized by upper respiratory complaints, headache, and mild fatigue, but the more serious CFS is often also associated with SBS(588).
Other Treatments for CFS and FM
Nutrition and nutritional support have been found to play significant roles in CFS/FM alleviation(580,386a,19,etc.). Adrenal fatigue related to long term stress and hypothyroidism are common factors in chronic fatigue(19). An adequate supply of vitamins and essential minerals as well as antioxidants have been found to benefit such conditions to counteract free radicals and oxidative stress caused by the conditions. Avoidance of too much sweets, sodas, high glycemic starches, etc. and more exercise such as walking, yoga, pilates, etc. can make major improvement in chronic fatigue(19). Adding more raw, steamed, and sauted greens, seafood, fruit, and other vegetables can also make a large difference. Glyconutrients such as Mannatech Ambrotose and Immunostart have also been found to be effective in reducing the effects of CFS and FM(528). Immunostart has been documented to be effective in detoxing toxic metals. Adrenal and/or thyroid fatigue can be reversed over time through such means along with adaptagenic herbs such as Cordyceps senensis, Rhodiola rosea, Aswagandha, Panax giseng, licorice root and supplementing Pantethine(B5), magnesium, vit C, DHEA, R-lipoic acis, and EFAs (19). Hormone testing such as Genova and ZRT lab tests along with morning temperature monitoring can help in assessing needs. Minerals often deficient related to thyroid fatigue include iodine, sea salt, selenium, magnesium, and zinc, along with the amino acid tyrosine and B vitamins. (19)
Some of the conditions found in people with CFS or FM or MCS include immune effects, energy metabolism problems, inflammation, adrenal fatigue, homocystein metabolism, fatigue, stress, brain neurotransmitter imbalances, leaky gut. (580,386a,etc.) In addition to metals detox, supplementation has been found clinically effective to deal with these conditions. Immune(ginseng, echineacea, EFAs, curcumin); energy metabolism(CoQ10, NADH, L-carnatine, magnesium) ; Adrenal fatigue(DHEA, licorice, sodium); Stress(glutamine, Adapton); neurotransmitters(tyrosine); homocysteine(B6,B12,folic acid, SAMe); inflammation(antioxidants: N-acetyl-cysteine, alpha lipoic acid), fatigue(ginseng, Mate), digestive support(digestive enzymes, probiotics) (580)
Tests are readily available to check for hormone levels often out of imbalance in these conditions such as DHEA, cortisol, thyroid, and testosterone in older men (386a,580,etc.).
B.E.Vickery’s testing showed all Fibromyalgia patients to have five common conditions, regardless of their symptoms: 1)protein deficiency 2)degenerating spinal disks 3)sulfur deficiency 4) heavy metal toxicity , and 5) viral infection. (585) It is claimed that if they follow the Vickory Protocol their bodies are able to heal.
(13)(a) S.Hussain et al, “Mercuric chloride‑induced reactive oxygen species and its effect on antioxidant enzymes in different regions of rat brain”,J Environ Sci Health B 1997 May;32(3):395‑409; & P.Bulat, “Activity of Gpx and SOD in workers occupationally exposed to mercury”, Arch Occup Environ Health, 1998, Sept, 71 Suppl:S37-9; & Stohs SJ, Bagchi D. Oxidative mechanisms in the toxicity of metal ions. Free Radic Biol Med 1995; 18(2): 321-36 ; & D.Jay, “Glutathione inhibits SOD activity of Hg”, Arch Inst cardiol Mex, 1998,68(6):457-61 & El-Demerdash FM. Effects of selenium and mercury on the enzymatic activities and lipid peroxidation in brain, liver, and blood of rats. J Environ Sci Health B. 2001 Jul;36(4):489-99. &(b) S.Tan et al, “Oxidative stress induces programmed cell death in neuronal cells”, J Neurochem, 1998, 71(1):95-105; & Matsuda T, Takuma K, Lee E, et al. Apoptosis of astroglial cells [Article in Japanese] Nippon Yakurigaku Zasshi. 1998 Oct;112 Suppl 1:24P-; & Lee YW, Ha MS, Kim YK.. Role of reactive oxygen species and glutathione in inorganic mercury-induced injury in human glioma cells. Neurochem Res. 2001 Nov;26(11):1187-93. & (c)Ho PI, Ortiz D, Rogers E, Shea TB. Multiple aspects of homocysteine neurotoxicity: glutamate excitotoxicity, kinase hyperactivation and DNA damage. J Neurosci Res. 2002 Dec 1;70(5):694-702.
(19) The 24 Hour Pharmacy, S. Cohen, R.Ph. 2008.
(20) (a) Galic N, Ferencic Z et al, Dental amalgam mercury exposure in rats. Biometals. 1999 Sep;12(3):227-31; & Arvidson B, Arvidsson J, Johansson K,. Mercury deposits in neurons of the trigeminal ganglia after insertion of dental amalgam in rats. Biometals. 1994 Jul;7(3):261-3; & (b)Danscher G, Horsted-Bindslev P, Rungby J. Traces of mercury in organs from primates with amalgam fillings. Exp Mol Pathol. 1990 Jun;52(3):291-9; & L.Hahn et al, Distribution of mercury released from amalgam fillings into monkey tissues”, FASEB J.,1990, 4:5536
(26) A.F.Zamm, “Removal of dental mercury: often an effective treatment for very sensitive patients”, J Orthomolecular Med, 1990, 5(53):138-142. (22 patients)
(33) (a) Markovich et al, "Heavy metals (Hg,Cd) inhibit the activity of the liver and kidney sulfate transporter Sat‑1", Toxicol Appl Pharmacol, 1999,154(2):181‑7; & (b)2S.A.McFadden, “Xenobiotic metabolism and adverse environmental response: sulfur- dependent detox pathways”,Toxicology, 1996, 111(1-3):43-65; &(c) S.C. Langley-Evans et al, “SO2: a potent glutathion depleting agent”, Comp Biochem Physiol Pharmocol Toxicol Endocrinol, 114(2):89-98; & (d)Alberti A, Pirrone P, Elia M, Waring RH, Romano C. Sulphation deficit in “low-functioning” autistic children. Biol Psychiatry 1999, 46(3):420-4.
(34) Henriksson J, Tjalve H. Uptake of inorganic mercury in the olfactory bulbs via olfactory pathways in rats. Environ Res. 1998 May;77(2):130-40.
(35) Huggins HA, Levy,TE, Uniformed Consent: the hidden dangers in dental care, 1999, Hampton Roads Publishing Company Inc; & CFS, www.hugginsappliedhealing.com/fatigue.php
(42) Rodgers JS, Hocker JR, et al, Mercuric ion inhibition of eukaryotic transcription factor binding to DNA. Biochem Pharmacol. 2001 Jun 15;61(12):1543-50; & K.Hansen et al A survey of metal induced mutagenicity in vitro and in vivo, J Amer Coll Toxicol , 1984:3;381‑430;
(43) (a)Knapp LT; Klann E. Superoxide‑induced stimulation of protein kinase C via thiol modification and modulation of zinc content. J Biol Chem 2000 May 22; & P.Jenner,“Oxidative mechanisms in PD”, Mov Disord, 1998; 13(Supp1):24-34;&(b) Rajanna B et al, “Modulation of protein kinase C by heavy metals”, Toxicol Lett, 1995, 81(2-3):197-203: & Badou A et al, “HgCl2-induced IL-4 gene expression in T cells involves a protein kinase C-dependent calcium influx through L-type calcium channels”J Biol Chem. 1997 Dec 19;272(51):32411-8., & D.B.Veprintsev, 1996, Institute for Biological Instrumentation, Russian Academy of Sciences, Pb2+ and Hg2+ binding to alpha‑lactalbumin”.Biochem Mol Biol Int 1996 ;39(6): 1255‑65; & M. J. McCabe, University of Rochester School of Medicine & Dentistry, 2002, Mechanisms of Immunomodulation by Metals, www.envmed.rochester.edu/envmed/TOX/faculty/mccabe.html; & Buzard GS, Kasprzak KS. Possible roles of nitric oxide and redox cell signaling in metal-induced toxicity and carcinogenesis: a review. Environ Pathol Toxicol Oncol. 2000;19(3):179-99
(49) Kingman A, Albertini T, Brown LJ. National Institute of Dental Research, “Mercury concentrations in urine and blood associated with amalgam exposure in the U.S. military population”, J Dent Res. 1998, 77(3):461-71
(54) M.E. Lund et al, “Treatment of acute MeHg poisoning by NAC”, J Toxicol Clin Toxicol, 1984, 22(1):31-49; & Livardjani F; Ledig M; Kopp P; Dahlet M; Leroy M; Jaeger A. Lung and blood superoxide dismustase activity in mercury vapor exposed rats: effect of N‑acetylcysteine treatment. Toxicology 1991 Mar 11;66(3):289‑95. & G.Ferrari et al, Dept. Of Pathology, Columbia Univ., J Neurosci,1995, 15(4):2857-66; & RR. Ratan et al, Dept. of Neurology, Johns Hopkins Univ., J Neurosci, 1994, 14(7): 4385-92;
(56)(a) A.Nicole et al, “Direct evidence for glutathione as mediator of apoptosis in neuronal cells”, Biomed Pharmacother, 1998; 52(9):349-55; & J.P.Spencer et al, “Cysteine & GSH in PD”, mechanisms involving ROS”, J Neurochem, 1998, 71(5):2112-22: & & J.S. Bains et al, “Neurodegenerative disorders in humans and role of glutathione in oxidative stress mediated neuronal death”, Brain Res Rev, 1997, 25(3):335-58;&
Medina S, Martinez M, Hernanz A, Antioxidants inhibit the human cortical neuron apoptosis induced by hydrogen peroxide, tumor necrosis factor alpha, dopamine and beta-amyloid peptide 1-42.. Free Radic Res. 2002 Nov;36(11):1179-84. &(b) Pocernich CB, et al. Glutathione elevation and its protective role in acrolein-induced protein damage in synaptosomal membranes: relevance to brain lipid peroxidation in neurodegenerative disease. Neurochem Int 2001 Aug;39(2):141-9; & D. Offen et al, “Use of thiols in treatment of PD”, Exp Neurol, 1996,141(1):32-9; & (c) Pearce RK, Owen A, Daniel S, Jenner P, Marsden CD. Alterations in the distribution of glutathione in the substantia nigra in Parkinson's disease. J Neural Transm. 1997;104(6-7):661-77; & A.D.Owen et al, Ann NY Acad Sci, 1996, 786:217-33; & JJ Heales et al, Neurochem Res, 1996, 21(1):35-39; & X.M.Shen et al, Neurobehavioral effects of NAC conjugates of dopamine: possible relevance for Parkinson’sDisease”, Chem Res Toxicol, 1996, 9(7):1117-26; & Chem Res Toxicol, 1998, 11(7):824-37; & (d) Li H, Shen XM, Dryhurst G. Brain mitochondria catalyze the oxidation of 7-(2-aminoethyl)-3,4-dihydro-5-hydroxy-2H-1,4-benzothiazine-3-carboxyli c acid (DHBT-1) to intermediates that irreversibly inhibit complex I and scavenge glutathione: potential relevance to the pathogenesis of Parkinson's disease. J Neurochem. 1998 Nov;71(5):2049-62; & (e) Araragi S, Sato M. et al, Mercuric chloride induces apoptosis via a mitochondrial-dependent pathway in human leukemia cells. Toxicology. 2003 Feb 14;184(1):1-9.
(60)V.D.M.Stejskal, Dept. Of Clinical Chemistry, Karolinska Institute, Stockholm, Sweden LYMPHOCYTE IMMUNO‑STIMULATION ASSAY ‑MELISA" & VDM Stejskal et al, "MELISA: tool for the study of metal allergy", Toxicology in Vitro, 8(5):991‑1000, 1994. http://www.melisa.org
(62) Dr. J.E. Hardy, Mercury Free: the wisdom behind the growing consumer moverment to ban silver dental fillings, 1998.
(79) L.Bjorkman et al, "Mercury in Saliva and Feces after Removal of Amalgam Fillings", Toxicology and Applied Pharmacology, 1997, 144(1), p156-62
(84) J.C.Veltman et al, “Alterations of heme, cytochrome P-450, and steroid metabolism by mercury in rat adrenal gland”, Arch Biochem Biophys, 1986, 248(2):467-78; & A.G.Riedl et al, Neurodegenerative Disease Research Center, King’s College,UK, “P450 and hemeoxygenase enzymes in the basal ganglia and their role’s in Parkinson’s disease”, Adv Neurol, 1999; 80:271-86; & Alfred V. Zamm. Dental Mercury: A Factor that Aggravates and Induces Xenobiotic Intolerance. J. Orthmol. Med. v6#2 pp67-77 (1991).
(87)A. Skoglund, Scand J Dent Res 102(4): 216‑222, 1994; and 99(4):320‑9,1991(40 cases); & P.O.Ostman et al, "Clinical & histologic changes after removal of amalgma", Oral Surgery, Oral Medicine, and Endodontics, 1996, 81(4):459‑465; & S.H.Ibbotson et al, "The relevance of amalgam replacement on oral lichenoid reactions", British Journal of Dermatology, 134(3):420‑3, 1996; & J.Bratel et al, "Effect of Replacement of Dental Amalgam on OLR", Journal of Dentistry, 1996, 24(1‑2):41‑45(. (431 cases)
(90)P.Koch et al, "Oral lesions and symptoms related to metals", Dermatol,1999,41(3):422‑430; & "Oral lichenoid lesions,mercury hypersensitity, ...", Contact Dermatitis, 1995, 33(5): 323‑328; & S.Freeman et al, "Orallichenoid lesions caused by allergy to mercury in amalgam", Contact Dermatitis, 33(6):423‑7, Dec 1995 (Denmark)
(94) F.Berglund, Case reports spanning 150 years on the adverse effects of dental amalgam, Bio-Probe, Inc.,Orlando,Fl,1995;ISBN 0-9410011-14-3(245 cured); & Tuthill JY, "Mercurial neurosis resulting from amalgam fillings", The Brooklyn Medical Journal, December 1898, v.12, n.12, p725-742
(95)H.J.Lichtenberg, "Elimination of symptoms by removal of dental amalgam from mercury poisoned patients", J Orthomol Med 8:145-148, 1993(120 patients); & “Symptoms before and after proper amalgamremoval in relation to serum globulin reaction to metals”,J of Orthomol Med., 1996, 11(4):195-9. (118 cases) http://www.lichtenberg.dk/symptoms_before_and_after_proper.htm
(96) A.F.Goldberg et al, “Effect of Amalgam restorations on whole body potassium and bone mineral content in older men”,Gen Dent, 1996, 44(3): 246-8; & (b) K.Schirrmacher,1998, “Effects of lead, mercury, and methyl mercury on gap junctions and [Ca2+]I in bone cells”, Calcif Tissue Int 1998 Aug;63(2):134‑9.
(111) (a) Quig D, Doctors Data Lab,"Cysteine metabolism and metal toxicity", Altern Med Rev, 1998;3:4, p262‑270, & (b) J.de Ceaurriz et al, Role of gamma‑ glutamyltraspeptidase(GGC) and extracellular glutathione in dissipation of inorganic mercury",J Appl Toxicol,1994, 14(3): 201‑; & W.O. Berndt et al, "Renal glutathione and mercury uptake", Fundam Appl Toxicol, 1985, 5(5):832‑9; & Zalups RK, Barfuss DW. Accumulation and handling of inorganic mercury in the kidney after coadministration with glutathione, J Toxicol Environ Health, 1995, 44(4): 385-99; & T.W.Clarkson et al, "Billiary secretion of glutathione‑metal complexes", Fundam Appl Toxicol, 1985, 5(5):816‑31;
(113)T.A.Glavinskiaia et al, "Complexons in the treatment of lupus erghematousus", Dermatol Venerol, 1980,12: 24‑28; & A.F.Hall, Arch Dermatol 47, 1943, 610‑611.
(114) (a)M.Aschner et al, “Metallothionein induction in fetal rat brain by in utero exposure to elemental mercury
vapor”, Brain Research, 1997, dec 5, 778(1):222-32; & Baauweegers HG, Troost D. Localization of metallothionein in the mammilian central nervous system.. Biol Signals 1994, 3:181-7. &(b) T.V. O’Halloran, “Transition metals in control Of gene expression”, Science, 1993, 261(5122):715-25; &(c) Matts RL, Schatz JR, Hurst R, Kagen R. Toxic heavy metal ions inhibit reduction of disulfide bonds. J Biol Chem 1991; 266(19): 12695-702; Boot JH. Effects of SH-blocking compounds on the energy metabolism in isolated rat hepatocytes. Cell Struct Funct 1995; 20(3): 233-8.;
(118) Tibbling L, Stejskal VDM, et al, Immunolocial and brain MRI changes in patients with suspected metal intoxication", Int J Occup Med Toxicol 4(2):285‑294,1995.
(119)(a) L.Ronnback et al, "Chronic encephalopaties induced by low doses of mercury or lead", Br J Ind Med 49: 233-240, 1992; & H.Langauer‑Lewowicka,” Changes in the nervous system due to occupational metallic mercury poisoning” Neurol Neurochir Pol 1997 Sep‑Oct;31(5):905‑13; &(b) Kim P, Choi BH. “Selective inhibition of glutamate uptake by mercury in cultured mouse astrocytes”, Yonsei Med J 1995; 36(3): 299-305; & Brookes N. In vitro evidence for the role of glutatmate in the CNS toxicity of mercury. Toxicology 1992, 76(3):245-56; & Albrecht J, Matyja E. Glutamate: a potential mediator of inorganic mercury toxicity. Metab Brain Dis 1996; 11:175-84.
(126)(a) Singh I, Pahan K, Khan M, Singh AK. Cytokine-mediated induction of ceramide production is redox-sensitive. Implications to proinflammatory cytokine-mediated apoptosis in demyelinating diseases. J Biol Chem. 1998 Aug 7;273(32):20354-62; & Pahan K, Raymond JR, Singh I. Inhibition of phosphatidylinositol 3-kinase induces nitric-oxide synthase in lipopolysaccharide- or cytokine-stimulated C6 glial cells. J. Biol. Chem. 274: 7528-7536, 1999; & Xu J, Yeh CH, et al, Involvement of de novo ceramide biosynthesis in tumor necrosis factor-alpha/cycloheximide-induced cerebral endothelial cell death. J Biol Chem. 1998 Jun 26;273(26):16521-6; & Dbaibo GS, El-Assaad W, et al, Ceramide generation by two distinct pathways in tumor necrosis factor alpha-induced cell death. FEBS Lett. 2001 Aug 10;503(1):7-12; & Liu B, Hannun YA.et al, Glutathione regulation of neutral sphingomyelinase in tumor necrosis factor-alpha-induced cell death.J Biol Chem. 1998 May 1;273(18):11313-20; & (b)Noda M, Wataha JC, et al, Sublethal, 2-week exposures of dental material components alter TNF-alpha secretion of THP-1 monocytes. Dent Mater. 2003 Mar;19(2):101-5; & Kim SH, Johnson VJ, Sharma RP. Mercury inhibits nitric oxide production but activates proinflammatory cytokine expression in murine macrophage: differential modulation of NF-kappaB and p38 MAPK signaling pathways. Nitric Oxide. 2002 Aug;7(1):67-74; & Dastych J, Metcalfe DD et al, Murine mast cells exposed to mercuric chloride release granule-associated N-acetyl-beta-D-hexosaminidase and secrete IL-4 and TNF-alpha. J Allergy Clin Immunol. 1999 Jun;103(6):1108-14; & (c) Tortarolo M, Veglianese P, et al, Persistent activation of p38 mitogen-activated protein kinase in a mouse model of familial amyotrophic lateral sclerosis correlates with disease progression.. Mol Cell Neurosci. 2003 Jun;23(2):180-92.
(142) Ariza ME; Bijur GN; Williams MV. Lead and mercury mutagenesis: role of H2O2, superoxide dismutase, and xanthine oxidase. Environ Mol Mutagen 1998;31(4):352‑61; & M.E. Ariza et al, “Mercury mutagenisis”, Biochem Mol Toxicol, 1999, 13(2):107-12; & M.E.Ariza et al, "Mutagenic effect of mercury", InVivo 8(4):559-63,1994
(152) Langworth et al, “Effects of low exposure to inorganic mercury on the human immune system”, Scand J Work Environ Health, 19(6): 405-413.1993; & Walum E et al, Use of primary cultures to sutdy astrocytic regulatory functions. Clin Exp Pharmoacol Physiol 1995, 22:284-7; & J Biol Chem 2000 Dec 8;275(49):38620-5; & (b)Kerkhoff H, Troost D, Louwerse ES. Inflammatory cells in the peripheral nervous system in motor neuron disease. Acta Neuropathol 1993; 85:560-5; & (c)Appel Sh, Smith RG. Autoimmunity as an etiological factor in amyotrophic lateral sclerosis. Adv Neurol 1995; 68:47-57.
(181)P.W. Mathieson, "Mercury: god of TH2 cells",1995, Clinical Exp Immunol.,102(2):229‑30;& & Heo Y, Parsons PJ, Lawrence DA, Lead differentially modifies cytokine production in vitro and in vivo. Toxicol Appl Pharmacol, 196; 138:149-57; & Murdoch RD, Pepys J; Enhancement of antibody and IgE production by mercury and platinum salts. Int Arch Allergy Appl Immunol 1986 80: 405-11.
(181) Mathieson PW, “Mercury: god of TH2 cells”,1995, Clinical Exp Immunol.,102(2):229-30; & (b) Heo Y, Parsons PJ, Lawrence DA, Lead differentially modifies cytokine production in vitro and in vivo. Toxicol Appl Pharmacol, 1996; 138:149-57; & (c) Murdoch RD, Pepys J; Enhancement of antibody and IgE production by mercury and platinum salts. Int Arch Allergy Appl Immunol 1986 80: 405-11;
(194) Lu SC, FASEB J, 1999, 13(10):1169‑83, “Regulation of hepatic glutathione synthesis: current concepts and
controversies”; & R.B. Parsons, J Hepatol, 1998, 29(4):595-602; & R.K.Zalups et al,"Nephrotoxicity of inorganic mercury co‑administered with L‑cysteine", Toxicology, 1996, 109(1): 15‑29.
(198) Cd2+ and Hg2+ affect glucose release and cAMP-dependent transduction pathway in isolated eel hepatocytes. Aquat Toxicol. 2003 Jan 10;62(1):55-65, Fabbri E, Caselli F, Piano A, Sartor G, Capuzzo A. & Fluctuation of trace elements during methylmercury toxication and chelation therapy. Hum Exp Toxicol. 1994 Dec;13(12):815-23, Bapu C, Purohit RC, Sood PP; & E.S. West et al, Textbook of Biochemistry, MacMillan Co, 1957,p853;& B.R.G.Danielsson et al,”Ferotoxicity of inorganic mercury: distribution and effects of nutrient uptake by placenta and fetus”, Biol Res Preg Perinatal. 5(3):102-109,1984; & Danielsson et al, Neurotoxicol. Teratol., 18:129-134;
(212)Ziff, M.F., "Documented Clinical Side Effects to Dental Amalgams", ADV. Dent. Res.,1992; 1(6):131‑134; & S.Ziff,Dentistry without Mercury, 8th Edition, 1996, Bio‑Probe, Inc., ISBN 0‑941011‑04‑6; & Dental Mercury Detox, Bio‑Probe, Inc. http://www.bioprobe.com. (cases:FDA Patient Adverse Reaction Reports‑762, Dr.M.Hanson‑Swedish patients‑519, Dr. H. Lichtenberg‑100 Danish patients,Dr. P.Larose‑ 80 Canadian patients, Dr. R.Siblerud, 86 Colorado patients,Dr. A.V.Zamm, 22 patients)
(222) M. Daunderer, Handbuch der Amalgamvergiftung, Ecomed Verlag, Landsberg 1998, ISBN 3‑609‑71750‑5 (in German); & "Improvement of Nerve and Immunological Damages after Amalgam Removal", Amer. J. Of Probiotic Dentistry and Medicine, Jan 1991;
(225)S. Yannai et al, "Transformationss of inorganic mercury by candida albicans and saccharomyces cerevisiae", Applied Envir Microbiology,1991, 7:245‑247; & N.E.Zorn et al, " A relationship between Vit B‑12, mercury
uptake, and methylation", Life Sci, 1990, 47(2):167‑73; & W.P.Ridley et al, Environ Health Perspectives, 1977, Aug 19, 43‑6; & R.E.DeSimone et al, Biochem Biophys Acta, 1973,May 28; & Yamada, Tonomura"Formation of methyl Mercury Compounds from inorganic Mercury by Chlostridium cochlearium" J Ferment Technol1972 50:159‑1660
(226) B.J. Shenker et al, Dept. Of Pathology,Univ. Of Penn. School of Dental Med.,”Immunotoxic effects of mercuric compounds on human lymphocytes and monocytes:Alterations in cell viability” Immunopharmacologicol Immunotoxical, 1992, 14(3):555-77; & M.A.Miller et al, “Mercuric chloride induces apoptosis in human T lymphocytes”, Toxicol Appl Pharmacol, 153(2):250‑7 1998; &(b) Rossi AD,Viviani B, Vahter M. Inorganic mercury modifies Ca2+ signals, triggers apoptosis, and potentiates NMDA toxicity in cerebral granule neurons. Cell Death and Differentiation 1997; 4(4):317-24. & Goering PL, Thomas D, Rojko JL, Lucas AD. Mercuric chloride-induced apoptosis is dependent on protein synthesis. Toxicol Lett 1999; 105(3): 183-95;
(229) M.Davis,editor, Defense Against Mystery Syndromes”, Chek Printing Co., March, 1994(case histories documented); & Andrew Hall Cutler, PhD, PE; Amalgam Illness:Diagnosis and Treatment; 1996 , www.noamalgam.com/
(230) Rogers S(MD), The E.I. Syndrome: An Rx for Environmental Illness, Keats Publishing, Amazon Books
(233)F.Berglund,Bjerner/Helm,Klock,Ripa,Lindforss,Mornstad,Ostlin), “Improved Health after Removal of dental amalgam fillings”, Swedish Assoc. Of Dental Mercury Patients, 1998. http://iaomt.org/articles/files/files214/Hansen-%20effects%20of%20amal%20removal.pdf
(234) P.E. Bigazzi, "Autoimmunity and Heavy Metals", Lupus, 1994; 3: 449‑453; & Pollard KM, Pearson Dl, Hultman P. Lupus‑prone mice as model to study xenobiotic‑induced autoimmunity. Environ Health Perspect 1999;
107(Suppl 5): 729‑735; & & Nielsen JB; Hultman P. Experimental studies on genetically determined susceptibility to mercury‑induced autoimmune response. Ren Fail 1999 May‑Jul;21(3‑4):343‑8; & Feighery L, Collins C, Anti-transglutaminase antibodies and the serological diagnosis of coeliac disease. Br J Biomed Sci. 2003;60(1):14-8; & & Mayes MD. Epidemiologic studies of environmental agents and systemic autoimmune diseases. Environ Health Perspect. 1999 Oct;107 Suppl 5:743-8; &. Bigazzi PE. Metals and kidney autoimmunity. Environ Health Perspect. 1999 Oct;107 Suppl 5:753-65
(235) H.J.Hamre, Mercury from Dental Amalga and Chronic Fatigue Syndrom", The CFIDS Chronicle, Fall 1994, p44‑47.
(252) B.J.Shenker et al, Dept. of Pathology, Univ. of Pennsylvania, “Immunotoxic effects of mercuric compounds on human lymphoctes and monocytes: Alterations in cellular glutathione content”, Immunopharmacol Immunotoxicol 1993, 15(2-3):273-90.
(254) al-Saleh I, Shinwari N. Urinary mercury levels in females: influence of dental amalgam fillings. Biometals 1997; 10(4): 315-23; & Zabinski Z; Dabrowski Z; Moszczynski P; Rutowski J. The activity of erythrocyte enzymes and basic indices of peripheral blood erythrocytes from workers chronically exposed to mercury vapors. Toxicol Ind Health 2000 Feb;16(2):58‑64.
(260) Woods JS et al, Altered porphyrin metabolites as a biomarker of mercury exposure and toxicity”, Physiol Pharmocol, 1996,74(2):210-15, & Strubelt O, Kremer J, et al, Comparative studies on the toxicity of mercury, cadmium, and copper toward the isolated perfused rat liver. J Toxicol Environ Health. 1996 Feb 23;47(3):267-83; & Kaliman PA, Nikitchenko IV, Sokol OA, Strel'chenko EV. Regulation of heme oxygenase activity in rat liver during oxidative stress induced by cobalt chloride and mercury chloride. Biochemistry (Mosc). 2001 Jan;66(1):77-82.; &(d) Kumar SV, Maitra S, Bhattacharya S. In vitro binding of inorganic mercury to the plasma membrane of rat platelet affects Na+-K+-Atpase activity and platelet aggregation. Biometals. 2002 Mar;15(1):51-7.
(263) Kumar AR, Kurup PA. Inhibition of membrane Na+-K+ ATPase activity: a common pathway in central nervous system disorders. J Assoc Physicians India. 2002 Mar;50:400-6; & Kurup RK, Kurup PA. Hypothalamic digoxin, cerebral chemical dominance and myalgic encephalomyelitis. Int J Neurosci. 2003 May;113(5):683-701, & (c) Kurup RK, Kurup PA. Hypothalamic digoxin, hemispheric dominance, and neuroimmune integration. Int J Neurosci. 2002 Apr;112(4):441-62; & (d) Kurup RK, Kurup PA, Hypothalamic digoxin and hemispheric chemical dominance--relation to the pathogenesis of senile osteoporosis, degenerative osteoarthritis, and spondylosis. Int J Neurosci. 2003 Mar;113(3):341-59.
(264) B.R. Danielsson et al, “ ”Behavioral effects of prenatal metallic mercury inhalation exposure in rats”, Neurotoxicol Teratol, 1993, 15(6): 391-6;& A. Fredriksson et al,”Prenatal exposure to metallic mercury vapour and methylmercury produce interactive behavioral changes in adult rats”, Neurotoxicol Teratol, 1996, 18(2): 129-34
(265)K.Lohmann et al, "Multiple Chemical Sensitivity Disorder in patients with neuroltoxic illnesses", Gesundheitswesen, 1996, 58(6):322‑31.
(268)J.J.Weening et al, "mercury induced immune complex glomerulopathy", Chap 4, p36‑66, VanDendergen, 1980, & P.Duuet et al, "Glomerulonephritis induced by heavy metals", Arch Toxicol. 50:187‑194,1982 & Transplantation
(269)(a)C.J.G.Robinson et al, "Mercuric chloride induced anitnuclear antibodies In mice", Toxic Appl Pharmacology, 1986, 86:159‑169. &(b) P.Andres, IgA‑IgG disease in the intestines of rats ingesting HgCl", Clin Immun Immunopath, 30:488‑494, 1984; &(c) F.Hirsch et al, J Immun.,136(9), 3272‑3276, 1986 & (d)J.Immun.,136(9):3277‑3281; & (e)J Immun., 137(8),1986,2548‑ & (f)Cossi et al, "Benefiecial effect of human therapeutic IV‑Ig in mercury indueced autoimune disease" Clin Exp Immunol, Apr, 1991; & (g)El‑Fawai HA, Waterman SJ, De Feo A, Shamy MY. Neuroimmunotoxicology: Humoral Assesment of Neurotoxicity and Autoimmune Mechinisms. Contact Dermatitis 1999; 41(1): 60‑1.
(270)D.W.Eggleston, "Effect of dental amalgam and nickel alloys on T‑lympocytes",J Prosthet Dent. 51(5):617‑623, 1984; & (d) Park SH et al, Effects of occupational metallic mercury vapor exposure on suppressor-inducer(CD4+CD45RA+) T lymphocytes and CD57+CD16+ natural killer cells, Int Arch Occup Environ Health, 2000, 73(8): 537-42.
(272) BJ Shenker,“Low-level MeHg exposure causes human T-cells to undergo apoptosis: evidence of mitochondrial disfunction”, Environ Res, 1998, 77(2):149-159; & O.Insug et al, “Mercuric compounds inhibit human monocyte function by inducing apoptosis: evidence for formation of reactive oxygen species(ROS), development of mitochondrial membrane permeability, and loss of reductive reserve”, Toxicology, 1997, 124(3):211-24;
(287) (Kurup RK, Kurup PA. Hypothalamic digoxin, cerebral chemical dominance, and pathogenesis of pulmonary diseases Int J Neurosci. 2003 Feb;113(2):235-58; & Anner BM, Moosmayer M, Imesch E. Mercury blocks Na-K-ATPase by a ligand-dependent and reversible mechanism.. Am J Physiol. 1992 May;262(5 Pt 2):F830-6; & Walczak-Drzewiecka A, Wyczolkowska J, Dastych J. Environmentally Relevant Metal and Transition Metal Ions Enhance Fc Epsilon RI-Mediated Mast Cell Activation. Environ Health Perspect. 2003 May;111(5):708-13. ); & Hunter I, Cobban HJ, Vandenabeele P, MacEwan DJ, Nixon GF. Tumor necrosis factor-alpha-induced activation of RhoA in airway smooth muscle cells: role in the Ca2+ sensitization of myosin light chain20 phosphorylation. Mol Pharmacol. 2003 Mar;63(3):714-21 )
(288) (a)Hisatome I, Kurata Y, et al; Block of sodium channels by divalent mercury: role of specific cysteinyl residues in the P-loop region. Biophys J. 2000 Sep;79(3):1336-45; & Bhattacharya S, Sen S et al, Specific binding of inorganic mercury to Na(+)-K(+)-ATPase in rat liver plasma membrane and signal transduction. Biometals. 1997 Jul;10(3):157-62; & Anner BM, Moosmayer M, Imesch E. Mercury blocks Na-K-ATPase by a ligand-dependent and reversible mechanism. Am J Physiol. 1992 May;262(5 Pt 2):F830-6. & Anner BM, Moosmayer M. Mercury inhibits Na-K-ATPase primarily at the cytoplasmic side. Am J Physiol 1992; 262(5 Pt2):F84308; & Wagner CA, Waldegger S,et al; Heavy metals inhibit Pi-induced currents through human brush-border NaPi-3 cotransporter in Xenopus oocytes.. Am J Physiol. 1996 Oct;271(4 Pt 2):F926-30; & Lewis RN; Bowler K. Rat brain (Na+‑K+)ATPase: modulation of its ouabain‑sensitive K+‑PNPPase activity by thimerosal. Int J Biochem 1983;15(1):5‑7
& (b) Rajanna B, Hobson M, Harris L, Ware L, Chetty CS. Effects of cadmium and mercury on Na(+)-K(+) ATPase and uptake of 3H-dopamine in rat brain synaptosomes. Arch Int Physiol Biochem 1990, 98(5):291-6; & M.Hobson, B.Rajanna, “Influence of mercury on uptake of dopamine and norepinephrine”, Toxicol Letters, Dep 1985, 27:2-3:7-14; & & McKay SJ, Reynolds JN, Racz WJ. Effects of mercury compounds on the spontaneous and potassium-evoked release of [3H]dopamine from mouse striatial slices. Can J Physiol Pharmacol 1986, 64(12):1507-14; & Scheuhammer AM; Cherian MG. Effects of heavy metal cations, sulfhydryl reagents and other chemical agents on striatal D2 dopamine receptors. Biochem Pharmacol 1985 Oct 1;34(19):3405‑13 ;& K.R.Hoyt et al, “Mechanisms of dopamine-induced cell death and differences from glutamate Induced cell death”, Exp Neurol 1997, 143(2):269-81; & (c)Offen D, et al, Antibodies from ALS patients inhibit dopamine release mediated by L-type calcium channels. Neurology 1998 Oct;51(4):1100-3.
(291) H.A.Huggins & TE Levy, "cerebrospinal fluid protein changes in MS after Dental amalgam removal", Alternative Med Rev, Aug 1998, 3(4):295‑300; & H.A. Huggins, Solving the MS Mystery, 2002, & http://www.hugginsappliedhealing.com/ms.php
(293)H.Huggins,Burton Goldberg, & Editors of Alternative Medicine Digest,Chronic Fatigue Fibromyalgia & Environmental Illness, Future Medicine Publishing, Inc, 1998, p197; & CFS, http://www.hugginsappliedhealing.com/fatigue.php
(296) L.Bucio et al, Uptake, cellular distribution and DNA damage produced by mercuric chloride in a human fetal hepatic cell line. Mutat Res 1999 Jan 25;423(1‑2):65‑72; & (b) Ho PI, Ortiz D, Rogers E, Shea TB. Multiple aspects of homocysteine neurotoxicity: glutamate excitotoxicity, kinase hyperactivation and DNA damage. J Neurosci Res. 2002 Dec 1;70(5):694-702; &(c) & Snyder RD; Lachmann PJ; Thiol involvement in the inhibition of DNA repair by metals in mammalian cells. Source Mol Toxicol, 1989, 2:2, 117‑28; & L.Verschaeve et al, “Comparative in vitro cytogenetic studies in mercury-exposed human lymphocytes”, Muta Res, 1985, 157(2-3): 221-6; & L.Verschaeve,“Genetic damage induced by low level mercury exposure”, Envir Res,12:306-10, 1976.
(304) Dietary Supplementation with Chlorella pyrenoidosa Produces Positive Results in Patients with Cancer or Suffering from Certain Common Chronic Illnesses, R.E. Merchant and C.A. Andre, Townsend Letter for Doctors & Patients, Feb/Mar 2001
(305) Soderstrom S, Fredriksson A, Dencker L, Ebendal T, “The effect of mercury vapor on cholinergic neurons in the fetal brain, Brain Research & Developmental Brain Res, 1995, 85:96-108; & Toxicol Lett 1995; 75(1-3): 133-44.; & (b)E.M. Abdulla et al, “Comparison of neurite outgrowth with neurofilament protein levels In neuroblastoma cells following mercuric oxide exposure”, Clin Exp Pharmocol Physiol, 1995, 22(5): 362-3: &(c) Leong CC, Syed NI, Lorscheider FL. Retrograde degeneration of neurite membrane structural integrity of nerve growth cones following in vitro exposure to mercury. Neuroreport 2001 Mar 26;12(4):733-7
(313) V.D.M.Stejskal et al, "Mercury‑specific Lymphocytes: an indication of mercury allergy in man", J. Of Clinical Immunology, 1996, Vol 16(1);31‑40.
(314) M.Goldman et al,1991,"Chemically induced autoimmunity ...",Immunology Today,12:223‑; & K. Warfyinge et al, "Systemic autoimmunity due to mercury vapor exposure in genetically susceptible mice", Toxicol Appl Pharmacol,
1995, 132(2):299‑309;& L.M. Bagenstose et al, "Mercury induced autoimmunity in humans", Immunol Res, 1999,20(1): 67‑78; &"Mercury‑induced autoimmunity", Clin Exp Immunol, 1998, 114(1):9‑12.
(316)B.J.Shenker et al, Dept. Of Pathology, Univ. Of Pennsylvania School of Dental Medicine, “Immunotoxic effects of mercuric compounds on human lymphocytes and monocytes: Alterations in B-cell function and viability” Immunopharmacol Immunotoxicol, 1993, 15(1):87-112; & J.R.Daum,”Immunotoxicology of mercury and cadmium on B-lymphocytes”, Int J Immunopharmacol, 1993, 15(3):383-94; & Johansson U, et al, "The genotype determines the B cell response in mercury-treated mice", Int Arch Allergy Immunol, 116(4):295-305, (Aug 1998)
(317) S.Zinecker, “Amalgam: Quecksilberdamfe bis ins Gehirn”, der Kassenarzt, 1992, 32(4):23; “Praxiproblem Amalgam”, Der Allgermeinarzt, 1995,17(11):1215-1221. (1800 patients)
(321) R.L.Siblerud, “Relationship between dental amalgam and health”, Toxic Substances Journal, 1990b. 10:425-444; & “Effects on health following removal of dental amalgams”, J Orthomolecular Med,5(2): 95-106, & “Relationship between amalgam fillings and oral cavity health” Ann Dent, 1990, 49(2): 6-10, (86 cured)
(323) Dr. Kohdera, Faculty of Dentistry, Osaka Univ, Internationsl Congress of Allergology and Clinical Immunology, EAACI, Stockholm, June 1994; & Heavy Metal Bulletin, Vol 1, Issue 2, Oct 1994. (160 cases cured‑eczema,etc.); Tsunetoshi Kohdera, MD, dermatology, allergology, 31 Higashitakada‑cho Mibu Nakagyo‑ku Schimazu Clinics Kyoto 604 Japan e‑mail:smc‑firstname.lastname@example.org‑inet.or.jp & G. Ionescu, Biol Med, 1996, (2): 65‑68; (these clinics use MELISA test for diagnosis of immune reactivity) Neukirchen (clinic)(Germany, near Czech border). Director; Gruia Ionescu, owns 2 Clinics, cases paid by insurance companies in Germany. Email: Spezialklinik‑Neukirchen@toolpool.de fax: 0049 9947 10 51 11
(330) Wilkinson LJ, Waring RH. Cysteine dioxygenase: modulation of expression in human cell lines by cytokines and control of sulphate production. Toxicol In Vitro. 2002 Aug;16(4):481-3; & (b) M.T.Heafield et al, "Plasma cysteine and sulphate levels in patients with Motor neurone disease, Parkinson's Disease, and Alzheimer's Disease", Neurosci Lett, 1990, 110(1‑2), 216,20; & A.Pean et al, "Pathways of cysteine metabolism in MND/ALS", J neurol Sci, 1994, 124, Suppl:59‑61; & Steventon GB, et al; Xenobiotic metabolism in motor neuron disease, The Lancet, Sept 17 1988, p 644-47; & Neurology 1990, 40:1095-98.
(331) C.Gordon et al, “Abnormal sulphur oxidation in systemic lupus erythrmatosus(SLE)”, Lancet, 1992,339:8784,25-6; &(b) P.Emory et al, “Poor sulphoxidation in patients with rheumatoid arthitis”, Ann Rheum Dis, 1992, 51:3,318-20; & Bradley H,et al, Sulfate metabolism is abnormal in patients with rheumatoid arthritis. Confirmation by in vivo biochemical findings. J Rheumatol. 1994 Jul;21(7):1192-6; & (c)T.L. Perry et al, “Hallevorden-Spatz Disease: cysteine accumulation and cysteine dioxygenase defieciency”, Ann Neural, 1985, 18(4):482-489.
(333) A.J.Freitas et al, “Effects of Hg2+ and CH3Hg+ on Ca2+ fluxes in the rat brain”, Brain Research, 1996, 738(2): 257-64; & P.R.Yallapragoda et al,“Inhibition of calcium transport by Hg salts” in rat cerebellum and cerebral cortex”, J Appl toxicol, 1996, 164(4): 325-30; & E.Chavez et al, “Mitochondrial calcium release by Hg+2",J Biol Chem, 1988, 263:8, 3582-; A. Szucs et al,Effects of inorganic mercury and methylmercury on the ionic currents of cultured rat hippocampal neurons. Cell Mol Neurobiol, 1997,17(3): 273-8; & D.Busselberg, 1995, “Calcium channels as target sites of heavy metals”,Toxicol Lett, Dec;82‑83:255‑61; & Cell Mol Neurobiol 1994 Dec;14(6):675‑87; & Rossi AD, et al, Modifications of Ca2+ signaling by inorganic mercury in PC12 cells. FASEB J 1993, 7:1507-14.
(338) (a)W.Y.Boadi et al, Dept. Of Food Engineering and Biotechnology, T-I Inst of Tech., Haifa, Israel, “In vitro effect of mercury on enzyme activities and its accumulation in the first-trimester human placenta”, Environ Res, 1992, 57(1):96-106;& “In vitro exposure to mercury and cadmium alters term human placental membrane fluidity”, Pharmacol, 1992, 116(1): 17-23; & (b)J.Urbach et al, Dept. of Obstetrics & Gynecology, Rambam Medical Center, Haifa, Israel, “Effect of inorganic mercury on in vitro placental nutrient transfer and oxygen consumption”, Reprod Toxicol, 1992,6(1):69-75;& © Karp W, Gale TF et al, Effect of mercuric acetate on selected enzymes of maternal and fetal hamsters” Environmental Research, 36:351-358; & W.B. Karp et al, “Correlation of human placental enzymatic activity with tracemetal concentration in placenta”, Environ Res. 13:470- 477,1977; & (d) Boot JH. Effects of SH‑blocking compounds on the energy metabolism and glucose uptake in isolated rat hepatocytes. Cell Struct Funct 1995 Jun;20(3):233‑8; & H.Iioka et al, “The effect of inorganic mercury on placental amino acid transport”, Nippon sanka Fujinka Gakkai Zasshi, 1987, 39(2): 202-6.
(342) Stejskal VDM, Danersund A, Lindvall A, Hudecek R, Nordman V, Yaqob A et al. Metal‑ specific memory lymphoctes: biomarkers of sensitivity in man. Neuroendocrinology Letters, 1999; 20: 289-298; & Sterzl I, Prochazkova J, Stejaskal VDM et al, Mercury and nickel allergy: risk facotrs in fatigue and autoimmunity. Neuroendocrinology Letters 1999; 20:221‑228.; & The beneficial effect of amalgam replacement on health in patients with autoimmunity. Prochazkova J, Sterzl I, Kucerova H, Bartova J, Stejskal VD; Neuro Endocrinol Lett. 2004 Jun;25(3):211-8. http://www.nel.edu/pdf_/25_3/NEL250304A07_Prochazkova_.pdf
(346) Clauw DJ, "The pathogenesis of chronic pain and fatigue syndroms: fibromyalgia" Med Hypothesis, 1995, 44:369‑78; & Hanson S, Fibromyalgia, glutamate, and mercury. Heavy Metal Bulletin, Issue 4, 1999, p3‑6.
(348) A Kistner, “Quecksilbervergiftung durch Amalgam: Diagnose und Therapie” ZWR, 1995,104(5):412-417; &(b) Villegas J, Martinez R, Andres A, Crespo D. Accumulation of mercury in neurosecretory neurons of mice after long-term exposure to oral mercuric chloride. Neurosci Lett 1999; 271: 93-96; &(c) Kozik MB, Gramza G. Histochemical changes in the neurosecretory hypothalic nuclei as a result of an intoxication with mercury compounds. Acta Histochem Suppl 1980; 22:367-80.
(368) Olin R, Paulander J, Axelsson P; FMS,CFS, and TMS- Prevalences in a Swedish County, An oral examination based study, Preventive Dental Health Care Center, Karlstad, Sweden, 1998.
(379) MacDonald EM, Mann AH, Thomas HC. Interferons as mediatorors of psychiatric morbidity. The Lancet 1978; Nov 21, 1175‑78; & Hickie I, Lloyd A. Are cytokines associated with neuropsychiatric syndrome in humans? Int J Immunopharm 1995; 4:285‑294.
(380) Komaroff AL, Buchwald DS. Chronic fatigue syndrom: an update. Ann Rev Med 1998; 49: 1‑13; & Buchwald DS, Wener MH, Kith P. Markers of inflamation and immune activation in CFS. J Rheumatol 1997; 24:372‑76.
(381) Demitrack MA,Dale JK. Evidence for impaired activation of the hypothalamic‑pituitary‑ adrenal axis in patients with chronic fatigue sydrome. J Clin endocrinol Metabol 1991; 73:1224‑ 1234; & Turnbull AV, Rivier C. Regulation of the HPA axis by cytokines. Brain Behav Immun 1995; 20:253‑75.
(382) Sterzl I, Fucikova T, Zamrazil V. The fatigue syndrome in autoimmune thyroiditis with Polyglanular activation of autoimmunity. Vnitrni Lekarstvi 1998; 44: 456‑60; & Sterzl I, Hrda P, Prochazkova J, Bartova J, Reactions to metals in patients with chronic fatigue and autoimmune endocrinopathy. Vnitr Lek 1999 Sep;45(9):527‑31
(383) Saito K. Analysis of a genetic factor of metal allergy‑polymorphism of HLA‑DR‑DO gene. Kokubyo Gakkai Zasschi 1996; 63: 53‑69; & Prochazkova J, Ivaskova E, Bartova J, Stejskal VDM. Immunogentic findings in patients with altered tolerance to heavy metals. Eur J Human Genet 1998; 6: 175.
(385) Kohdera T, Koh N, Koh R. Antigen‑specific lympocyte stimulation test on patients with psoriasis vulgaris. XVI International Congress of Allergology and Clinical Immunology, Oct 1997, Cancoon, Mexico; & Ionescu
G. Schwermetallbelastung bei atopischer Dermatitis und Psoriasis. Biol Med 1996; 2:65‑68.
(386) Genova Diagnostics,[click: Tests, Search by Disease, see Disease in question & Heavy Metal Toxicity], www.genovadiagnostics.com/ ; & Doctors Data Lab ,http://www.doctorsdata.com , inquiries @doctors data.com, & MetaMatrix Lab, http://www.metamatrix.com & Biospectron Lab .......
(404) M. E. Godfrey, Candida, Dysbiosis and Amalgam. J. Adv. Med. vol 9 no 2 (1996).
(405) Jenny Stejskal, Vera Stejskal. The role of metals in autoimmune diseases and the link to neuroendocrinology Neuroendocrinology Letters, 20:345‑358, 1999; www.melisa.org & ………..Factors in susceptibility to mercury toxicity, www.flcv.ccom/suscept.html
(411) Puschel G, Mentlein R, Heymann E, 'Isolation and characterization of dipeptyl peptidase IV from human placenta', Eur J Biochem 1982 Aug;126(2):359-65; & Kar NC, Pearson CM. Dipeptyl Peptidases in human muscle disease. Clin Chim Acta 1978; 82(1-2): 185-92; & Seroussi K, Autism and Pervasive Developmental Disorders , 1998, p174,etc.; & Shibuya-Saruta H, Kasahara Y, Hashimoto Y. Human serum dipeptidyl peptidase IV (DPPIV) and its unique properties. J Clin Lab Anal. 1996;10(6):435-40; & Blais A, Morvan-Baleynaud J, Friedlander G, Le Grimellec C. Primary culture of rabbit proximal tubules as a cellular model to study nephrotoxicity of xenobiotics. Kidney Int. 1993 Jul;44(1):13-8
(416)(a) Plaitakis A, Constantakakis E. Altered metabolism of excitatory amino acids, N-acetyl-aspartate and – acetyl-aspartyl-glutamate in amyotrophic lateral sclerosis. Brain Res Bull 1993;30(3-4):381-6 &(b)Rothstein JD, Martin LJ, Kuncl RW. Decreased glutamate transport by the brain and spinal cord in ALS. New Engl J Med 1992, 326: 1464-8:& (c) Leigh Pn. Pathologic mechanisms in ALS and other motor neuron diseases. In: Calne DB(Ed.), Neurodegenerative Diseases, WB Saunder Co., 1997, p473-88; & P.Froissard et al, Universite de Caen, “Role of glutathione metabolism in the glutamate-induced programmed cell death of neuronal cells” Eur J Pharmacol, 1997, 236(1): 93-99; & (d) Kim P, Choi BH. “Selective inhibition of glutamate uptake by mercury in cultured mouse astrocytes”, Yonsei Med J 1995; 36(3): 299-305; & Brookes N. In vitro evidence for the role of glutatmate in the CNS toxicity of mercury. Toxicology 1992, 76(3):245-56; & Albrecht J, Matyja E. Glutamate: a potential mediator of inorganic mercury toxicity. Metab Brain Dis 1996; 11:175-84; &(e) Tirosh O, Sen CK, Roy S, Packer L. Cellular and mitochondrial changes in glutamate-induced HT4 neuronal cell death Neuroscience. 2000;97(3):531-41;
(417) Folkers K et al, Biochemical evidence for a deficiency of vitamin B6 in subjects reacting to MSL‑Glutamate. Biochem Biophys Res Comm 1981, 100: 972; & Felipo V et al, L‑ carnatine increases the affinity of glutamate for quisqualate receptors and prevents glutamate neurotoxicity. Neurochemical Research 1994, 19(3): 373‑377; & Akaike A et al, Protective effects of a vitamin‑B12 analog(methylcobalamin, against glutamate cytotoxicity in cultured cortical neurons. European J of Pharmacology 1993, 241(1):1‑6 .
(432) Sutton KG, McRory JE, Guthrie H, Snutch TP. P/Q-type calcium channels mediate the activity-dependent feedback of syntaxin-1A. Nature 1999, 401(6755):800-4;
(440) Kidd RF. Results of dental amalgam removal and mercury detoxification. Altern Ther Health Med 2000 Jul;6(4):49‑55.
(442) Olanow CW, Arendash GW. Metals and free radicals in neurodegeneration. Curr Opin Neurol 1994, 7(6):548- 58; & Kasarskis EJ(MD), Metallothionein in ALS Motor Neurons(IRB #91-22026), FEDRIP DATABASE, National Technical Information Service(NTIS), ID: FEDRIP/1999/07802766.
(456) Panasiuk J , Peripheral blood lymphocyte transformation test in various skin diseases of allergic origin. (nickel & lupus) Przegl Dermatol 1980;67(6):823‑9 [Article in Polish] ; & Barnett JH, Discoid lupus erythematosus exacerbated by contact dermatitis. Cutis 1990 Nov;46(5):430‑2 (nickel & lupus) & Nickel Allergy Is Found in a Majority of Women with Chronic Fatigue Syndrome and Muscle Pain– And May Be Triggered by Cigarette Smoke and Dietary Nickel Intake; Journal of Chronic Fatigue Syndrome, Vol. 8(1) 2001
(462) Olivieri G; Brack C; Muller‑Spahn F; Stahelin HB; Herrmann M; Renard P; Brockhaus M; Hock C. Mercury induces cell cytotoxicity and oxidative stress and increases beta‑amyloid secretion and tau phosphorylation in SHSY5Y neuroblastoma cells. J Neurochem 2000 Jan;74(1):231‑6; & (b) Tabner BJ, Turnbull S, El-Agnaf OM, Allsop D. Formation of hydrogen peroxide and hydroxyl radicals from A(beta) and alpha-synuclein as a possible mechanism of cell death in Alzheimer's disease and Parkinson's disease. Free Radic Biol Med. 2002 Jun 1;32(11):1076-83; &(c) Ho PI, Collins SC, et al; Homocysteine potentiates beta-amyloid neurotoxicity: role of oxidative stress. J Neurochem. 2001 Jul;78(2):249-53.
(468) Overzet K, Gensler TJ, Kim SJ, Geiger ME, van Venrooij WJ, Pollard KM, Anderson P, Utz PJ. Small nucleolar RNP scleroderma autoantigens associate with phosphorylated serine/arginine splicing factors during apoptosis. Arthritis Rheum 2000 Jun;43(6):1327‑36
(469)BrainRecovery.com, the book, by David Perlmutter MD; Perlmutter Health Center, Naples, Florida, www.perlhealth.com/about.htm; & M.M. van Benschoten, “Acupoint Energetics of Mercury Toxicity and Amalgam Removal with Case Studies,” American Journal of Acupuncture, Vol. 22, No. 3, 1994, pp. 251-262, , Reseda, Calif. Clinic; www.mmvbs.com
(470) Dr. Garth Nicholson, Institute for Molecular Medicine, Huntington Beach, Calif., www.immed.org
& Michael Guthrie, R.Ph. ImmuneSupport.com 07‑18‑2001 Mycoplasmas – The Missing Link in Fatiguing Illnesses, www.immunesupport.com/library/showarticle.cfm?ID=3066; & New Treatments for Chronic Infections Found in Fibromyalgia Syndrome, Chronic Fatigue Syndrome, Rheumatoid Arthritis, and Gulf War Illnesses, http://www.immed.org/reports/autoimmune_illness/rep1.html ; & Prof. Garth L. Nicolson, Chronic Fatigue Syndrome, Fibromyalgia Syndrome and Other Fatigue Conditions, http://www.immed.org/illness/fatigue_illness_research.html
(471) Schwartz RB, Garada BM, Komaroff AL, Gleit M, Holman BL. Detection of intracranial abnormalities in patients with chronic fatigue syndrome: comparison of MRI and SPECT. Am J Roentgenol, 1994, 162(4):935‑41; & Spect Imaging: comparison of findings in patients with CFS, AIDA dementia complex, and major unipolar depression, Am J Roentgenol 1994, 162(4): 943‑51; & Ichiso M, Salit IE, Abbey SE. Assessment of regional cerebral perfusion by SPECT in CFS. Nucl Med Commun 1992; 13:767-72.
(472) Patarca‑Monero R, Klimas NG, Fletcher MA. Immunotherapy of chronic fatigue syndrome. Journal of Chronic Fatigue Syndrome. 2001, 8(1): 3‑37; & DeBecker P, De Meirleir K, Joos E, Velkeniers B. DHEA response to I.V. ACTH in patients with CFS. Horm Metab Res 1999, 31(1): 18‑21.
(473) De Meirleir K, Bisbal C, Campine I, De Becker, et al. A 37 kDa 1‑5A binding proein as a potential biochemical marker for CFS. Am J Med 2000, 108(2): 99‑105; & Suhadolnik RJ, Peterson DL, Obrien K, et al, Biochemical evidence for a novel low molecular weight 2‑5A‑dependent Rnase L in CFS. J Interferon Cytokine Res, 1997, 17(7): 377‑85; & Chaudhuri A, Watson WS, Pearn J, Behan PO. The symptoms of chronic fatigue syndrome are related to abnormal ion channel function. Med Hypotheses 2000 Jan;54(1):59‑63
(474) Richards SCM, Bell J, Cheung, YL, Cleare A, Scott DL. Muscle metabolites detected in urine in FM and CFS suggest ongoing muscle damage. Conference Proceedings of the British Scociety of Rheumatologists, April
2001, Scotland, Abstract 382; http://freespace,virgin.net/david.axford/me_nb_o4.htm.
(485) Hulda Clark, The Cure for all Diseases, 2000, www.drclark.net.
(487) Straus SE et al, CFS and allergy, J Allergy Clin Immunol, 1988, 81(5): 791-95; Straus SE et al, Evidence of Epstein-Barr virus infection in CFS, Annals of Internal Med, 1985, 102(1): 7-16; & Jones JF et al, Annals of Internal Med, Evidence for active Epstein-Barr Virus in patients with chronic unexplained illness, 1985, Annals of Internal Med, 102(1): 1-6; & Tyler AN, Influenza A virus: factor in fibromyalgia?, 1997, 2(2): 82- 86.
(488) Teitelbaum J, Bird B; Effective treatment of CFS, report on 64 patients, J Musculoskeletal Pain, 1995, 3(4): 91-100.
(489) Behan PO et al; Effect of high doses of essential fatty acids on postviral fatigue syndrome, Acta Neurol Scand, 1990, 82: 209-216; & Abraham GE, Flechas JD; Rationale for the use of magnesium and malic acid in fibromyalgis treatment, Journal of Nutritional Medicine, 1992, 3:40-52.
(490) Smith JD, Terpening CM, Schmidt SO, Gums JG. Relief of fibromyalgia symptoms following discontinuation of dietary excitotoxins. Ann Pharmacother 2001 Jun;35(6):702‑6.
(490) Shibata N, Nagai R, Kobayashi M. Morphological evidence for lipid peroxidation and protein glycoxidation in spinal cords from sporadic amyotrophic lateral sclerosis patients. Brain Res 2001 Oct 26;917(1):97-104 & Cookson MR, Shaw PJ. Oxidative stress and motor neurons disease. Brain Pathol 1999 Jan;9(1):165‑86.
(494) (a)Kobayashi MS, Han D, Packer L. Antioxidants and herbal extracts protect HT-4 neuronal cells against glutamate-induced cytotoxicity. Free Radic Res 2000 Feb;32(2):115-24(PMID: 10653482; & (Bridi R, Crossetti FP, Steffen VM, Henriques AT. The antioxidant activity of standardized extract of Ginkgo biloba (EGb 761) in rats. Phytother Res 2001 Aug;15(5):449-51 ;&(c)Li Y, Liu L, Barger SW, Mrak RE, Griffin WS. Vitamin E suppression of microglial activation is neuroprotective. J Neurosci Res 2001 Oct 15;66(2):163-70.
(496) Doble A. The role of excitotoxicity in neurodegenerative disease: implications for therapy. Pharmacol Ther 1999 Mar;81(3):163‑221; & Urushitani M, Shimohama S. N‑methyl‑D‑aspartate receptor‑mediated mitochondrial Ca(2+) overload in acute excitotoxic motor neuron death: a mechanism distinct from chronic neurotoxicity after Ca(2+) influx. J Neurosci Res 2001 Mar 1;63(5):377‑87; & Cookson MR, Shaw PJ. Oxidative stress and motor neurons disease. Brain Pathol 1999 Jan;9(1):165‑86
(502) Vielhaber S, Kaufmann J, Kunz WS. Effect of Creatine Supplementation on Metabolite Levels in ALS Motor Cortices. Exp Neurol 2001 Dec;172(2):377-82.
(518) Landay AL, Jessop C, Lenette ET, chronic fatigue syndrome: clinical condition associated with immune activation. Lancet 1991; 338:707-12; & (b)Caliguri M, Murray C, Buchwald D. Phenotypic and functional deficiency of natural killer cells in patients with CFS. J Immunol 1987; 139:3306-13; & Barker E, Fujirmura SF, Fadern MB. Immunologic abnormalities associated with CFS. Clin Infect Dis 1994; 18: 136-41.
(521) Guermonprez L, Ducrocq C, Gaudry-Talarmain YM. Inhibition of acetylcholine synthesis and tyrosine nitration induced by peroxynitrite are differentially prevented by antioxidants. Mol Pharmacol 2001 Oct;60(4):838-46; & & (b)Mahboob M, Shireen KF, Atkinson A, Khan AT. Lipid peroxidation and antioxidant enzyme activity in different organs of mice exposed to low level of mercury. J Environ Sci Health B. 2001 Sep;36(5):687-97. & Miyamoto K, Nakanishi H, et al, Involvement of enhanced sensitivity of N-methyl-D-aspartate receptors in vulnerability of developing cortical neurons to methylmercury neurotoxicity. Brain Res. 2001 May 18;901(1-2):252-8; & (c) Anuradha B, Varalakshmi P. Protective role of DL-alpha-lipoic acid against mercury-induced neural lipid peroxidation. Pharmacol Res. 1999 Jan;39(1):67-80.
(523) CBS Television Network,” 60 Minutes”, television program narrated by Morley Safer, December 12, 1990
(524) Urushitani M, Shimohama S. The role of nitric oxide in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord 2001 Jun;2(2):71-81; & Torreilles F, Salman-Tabcheh S, Guerin M, Torreilles J. Neurodegenerative disorders: the role of peroxynitrite.Brain Res Brain Res Rev 1999 Aug;30(2):153-63; & Aoyama K, Matsubara K, Kobayashi S. Nitration of manganese superoxide dismutase in cerebrospinal fluids is a marker for peroxynitrite-mediated oxidative stress in neurodegenerative diseases. Ann Neurol 2000 Apr;47(4):524-7; & Guermonprez L, Ducrocq C, Gaudry-Talarmain YM. Inhibition of acetylcholine synthesis and tyrosine nitration induced by peroxynitrite are differentially prevented by antioxidants. Mol Pharmacol 2001 Oct;60(4):838-46
(527) Cline Medical Center, Vancouver Island, http://www.oceansidemedicine.com/Default.htm
(528) Goldenberg DL;. Fibromyalgia, chronic fatigue syndrome, and myofascial pain. Curr Opin Rheumatol. 1996; 8: 113-123.
(529) GLYCONUTRITIONAL IMPLICATIONS IN FIBROMYALGIA AND CHRONIC FATIGUE SYNDROME http://www.glycoscience.org/glycoscience/start_frames.wm?FILENAME=G005&MAIN=glyconutritionals&SUB=disease
(537) Amalgam replacement with detox using NDF, case histories, www.healthydetox.org/cases.html
(572) Packer L, Tritschler HJ, Wessel K. Neuroprotection by the metabolic antioxidant alpha-lipoic acid. Free Radic Biol Med 1997;22(1-2):359-78(PMID: 8958163); & McCarty MF. Versatile cytoprotective activity of lipoic acid may reflect its ability to activate signalling intermediates that trigger the heat-shock and phase II responses. Med Hypotheses 2001 Sep;57(3):313-7 & Whiteman M, Tritschler H, Halliwell B. Protection against peroxynitrite-dependent tyrosine nitration and alpha 1-antiproteinase inactivation by oxidized and reduced lipoic acid. FEBS Lett 1996 Jan 22;379(1):74-6(PMID: 8566234); & Patrick L. Mercury toxicity and antioxidants: Part 1: role of glutathione and alpha-lipoic acid in the treatment of mercury toxicity. Altern Med Rev. 2002 Dec;7(6):456-71.
(575) XMRV- CFS/ME http://www.youtube.com/watch?v=_WEUC7hRXzM
(580) Life Extension Foundation (MDs), Disease Prevention and Treatment, Expanded 4th Edition, 2003 , http://www.life-enhancement.com/
(582) R.F. Kidd, Results of Dental Amalgam Removal and Mercury Detoxification, Alternative Therapies, July 2000, vol 6, no. 4, p49-55.
(583) Dr. Ronald King, DDS, Patient Experience After Amalgam Replacement, http://www.kingtooth.com/My-Histories-11-20-04.htm
(585) Fibromyalgia causes and treatment, B. E. Vickory, http://www.abctohealth.com/8.html?sm=11953
(586) (304) Fibromyalgia Syndrome and Heavy Metal Toxicity, Dietrich Klinghardt, MD, Ph.D. www.neuraltherapy.com/FibromyalgiaHeavyMetal.doc
(588) The natural history of concurrent sick building syndrome and chronic fatigue syndrome; Chester AC, Levine PH; J Psychiatr Res. 1997 Jan-Feb;31(1):51-7; & Concurrent sick building syndrome and chronic fatigue syndrome: epidemic neuromyasthenia revisited; Chester AC, Levine PH; Clin Infect Dis. 1994 Jan;18 Suppl 1:S43-8.
(590) Mercury toxicity presenting as chronic fatigue, memory impairment and depression: Diagnosis, treatment, susceptibility, and outcomes in a New Zealand general practice setting (1994–2006), D. P. Wojcik, M. E. Godfrey, D. Christie3 & B. E. Haley, Neuroendocrinology Letters Volume 27 No. 4 September 2006
(594) (a) Hidden Causes of GI Dysfunction, C.D. Meletis, Vitamin Research News, vol 22, no.4, April 2008; & (b) Are You the Victim of Hidden Allergies?, The Blaylock Wellness
(598) Overcoming Depression, Dr. Russell Blaylock, The Blaylock Wellness Report, Vol 5, No. 3, March 2008, & Food Additives, What you eat can kill you, Vol 4, No. 10, www.blaylockreport.com/
(600) B. Windham, Annotated bibliography: Exposure levels and health effects related to mercury/dental amalgam and results of amalgam replacement, 2002; (over 1500 medical study references documenting mechanism of causality of 40 chronic conditions and over 60,000 clinical cases of recovery or significant improvement of these conditions after amalgam replacement-documented by doctors) www.flcv.com/damspr1.html (exposure levels) &
(603) B. Windham(Ed.), The environmental effects of dental amalgam affect everyone, 2002,